Recent News

• 02.04.2026 - XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
• 02.04.2026 - XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
• 12.31.2025 - XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
• 12.31.2025 - XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
• 10.29.2025 - XORTX Announces Closing of US$1.1 Million Registered Direct Offering
• 10.29.2025 - XORTX Announces Closing of US$1.1 Million Registered Direct Offering
• 10.21.2025 - XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
• 10.21.2025 - XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

Recent Filings

• 01.02.2026 - EX-99.1 EX-99.1
• 01.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.17.2025 - EX-99.1 EX-99.1
• 10.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.31.2025 - EX-99.1 EX-99.1
• 10.29.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.27.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.23.2025 - EX-99.1 EX-99.1